CAS: 1033767-86-0

BAY-474 is a combination of two active compounds, vegfr and mapk inhibitors. It has been shown to be effective for the treatment of bladder cancer in vitro and in vivo. BAY-474 is administered intraperitoneally for prophylaxis purposes. BAY-474 may also be used for the treatment of other types of cancers that have a high incidence of vascular endothelial growth factor (VEGF) expression, such as nasal cancer. The drug is solvated with an organic solvent, which may help to stabilize the drug's activity and improve its pharmacokinetics.

BAY-474 is an inhibitor of tyrosine-protein kinase c-Met. It acts as an epigenetics probe

BAY-474